SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
The uncontrolled spread of the COVID-19 pandemic caused by the new coronavirus SARS-
CoV-2 during 2020–2021 is one of the most devastating events in the history, with …
CoV-2 during 2020–2021 is one of the most devastating events in the history, with …
Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro
H Liu, F Ye, Q Sun, H Liang, C Li, S Li… - Journal of enzyme …, 2021 - Taylor & Francis
COVID-19 has become a global pandemic and there is an urgent call for develo** drugs
against the virus (SARS-CoV-2). The 3C-like protease (3CLpro) of SARS-CoV-2 is a …
against the virus (SARS-CoV-2). The 3C-like protease (3CLpro) of SARS-CoV-2 is a …
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
The 3C-like protease (3CLpro) of SARS-CoV-2 is considered an excellent target for COVID-
19 antiviral drug development because it is essential for viral replication and has a cleavage …
19 antiviral drug development because it is essential for viral replication and has a cleavage …
Develo** a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment
The coronavirus disease 2019 (COVID-19) global pandemic resulted in millions of people
becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Structure-guided design of potent inhibitors of SARS-CoV-2 3CL protease: structural, biochemical, and cell-based studies
The COVID-19 pandemic is having a major impact on public health worldwide, and there is
an urgent need for the creation of an armamentarium of effective therapeutics, including …
an urgent need for the creation of an armamentarium of effective therapeutics, including …
[HTML][HTML] A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition
The likelihood of continued circulation of COVID-19 and its variants, and novel
coronaviruses due to future zoonotic transmissions, combined with the current paucity of …
coronaviruses due to future zoonotic transmissions, combined with the current paucity of …
Cellular activities of SARS-CoV-2 main protease inhibitors reveal their unique characteristics
As an essential enzyme of SARS-CoV-2, the pathogen of COVID-19, main protease (MPro)
triggers acute toxicity to its human cell host, an effect that can be alleviated by an MPro …
triggers acute toxicity to its human cell host, an effect that can be alleviated by an MPro …
The SARS-CoV-2 main protease doesn't induce cell death in human cells in vitro
A Komissarov, M Karaseva, M Roschina, S Kostrov… - Plos one, 2022 - journals.plos.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus
disease 2019 (COVID-19) which has extremely rapidly spread worldwide. In order to …
disease 2019 (COVID-19) which has extremely rapidly spread worldwide. In order to …